{
  "retracted": false,
  "timestamp": 1388534400000,
  "updates": [
    {
      "timestamp": 1585511573584,
      "identifier": {
        "doi": "10.1016/j.pain.2013.10.020"
      },
      "type": "err"
    }
  ],
  "identifier": {
    "doi": "10.1016/j.pain.2013.05.051"
  },
  "publisher": "Ovid Technologies (Wolters Kluwer Health)",
  "title": "Erratum to: “Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain” [PAIN® 2013;154(10):1910–19]"
}
